Leena Gandhi

Leena Gandhi is an expert in lung cancer immunotherapy who has led landmark clinical trials combining chemotherapy with checkpoint inhibitors. Her work on the KEYNOTE-189 trial established pembrolizumab plus chemotherapy as first-line standard-of-care for metastatic NSCLC, transforming treatment paradigms.

Leena Gandhi是肺癌免疫治疗专家，领导了将化疗与检查点抑制剂相结合的里程碑临床试验。她在KEYNOTE-189试验上的工作确立了pembrolizumab加化疗作为转移性NSCLC的一线标准治疗，改变了治疗范式。